Jill Marie Broadfoot - 03 Feb 2023 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role: Chief Financial Officer
Signature: /s/ Nancy E. Denyes, attorney-in-fact
Issuer symbol: ATYR
Transactions as of: 03 Feb 2023
Net transactions value: -$3,696
Form type: 4
Filing time: 06 Feb 2023, 18:00:37 UTC
Previous filing: 15 Jul 2022
Next filing: 21 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LIFE	Common stock	Options Exercise		+3,750	+28%		17,026	03 Feb 2023	Direct	F1, F2, F3
transaction	LIFE	Common stock	Sale	$3,696	-1,566	-9.2%	$2.36	15,460	06 Feb 2023	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIFE	Restricted Stock Unit	Options Exercise	$0	-3,750	-25%	$0.000000	11,250	03 Feb 2023	Common Stock	3,750		Direct	F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2	Restricted stock units convert into common stock on a one-for-one basis.
F3	Includes 986 shares acquired under that Company's 2015 Employee Stock Purchase Plan on November 15, 2022.
F4	Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F5	The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.